The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Use of the PRO Onc Assay (Prometheus) to measure HER2 overexpression/activation in circulating tumor cells (CTCs) in women with HER2-negative metastatic breast cancer (MBC): A Sarah Cannon Research Institute (SCRI) trial.
John D. Hainsworth
No relevant relationships to disclose
Howard A. Burris
No relevant relationships to disclose
Patrick Brian Murphy
No relevant relationships to disclose
Ruth E. Lamar
No relevant relationships to disclose
Mythili Shastry
No relevant relationships to disclose
Lindsey H. Finney
No relevant relationships to disclose
Denise Aysel Yardley
Consultant or Advisory Role - Genentech (U)